Business Wire

ZeroFOX Embraces Partner-First Strategy to Further Accelerate Rapid Growth, Launches New Global Partner Program

Share

ZeroFOX, leader in External Threat Intelligence and Protection, today announced the launch of the ZeroFOX Global Partner Program, a strategic pivot to a partner-first strategy. This move significantly increases ZeroFOX’s investment in partner enablement and commitment to conducting all business with and through their full partner ecosystem.

Another leap forward following the company’s significant expansion of cyber threat intelligence capabilities and addition of three 24/7 global security operations centers (SOCs), ZeroFOX’s partner-first strategy will accelerate capabilities for new and existing customers. Supported by a three-tier structure with escalating benefits, including graduating sales incentives, white glove support and marketing development funds, the Global Partner Program also offers a comprehensive go-to-market toolbox to meet the on-demand needs of a global salesforce. Specialized, entrepreneurial partner organizations with access to strategic geographic and vertical markets will be supported through an incubator program that incentivizes successful marketing initiatives, achieving training goals and overall business velocity.

Gartner forecasts that worldwide IT spending will increase 6.2% this year compared to last, reaching $3.9 trillion. Amid this tech growth, businesses are re-examining their cybersecurity approach. In fact, over half (55%) of tech and security executives plan to increase their cyber budgets this year, according to a recent PwC survey. With remote work and digital dependency – including an influx in social media use driven by the pandemic – contributing directly to this rise in attacks, it’s essential that the cybersecurity industry works to drive resiliency across markets.

“Our partners rely on ZeroFOX’s unmatched pace of innovation and commitment to delivering the world’s strongest external threat intelligence service. Together, we have put ourselves in a position to deliver unrivaled protection, intelligence, and disruption capabilities to all of our customers,” said James C. Foster, CEO of ZeroFOX. “Furthermore, our customers appreciate that as a partner-first organization, we invest in differentiated partner solutions. Our AI platform is a true difference maker for our partners and customers alike.”

With ZeroFOX’s Global Partner Program, partners and MSSPs seeking to increase customer value will be provided a rich set of professional services capabilities that ultimately enrich their core offering. To lead the charge, ZeroFOX has hired a full global partnerships team of channel veterans, including a dedicated team of channel partner directors, solution engineers and marketing experts, led by ZeroFOX Vice President of Global Partnerships, Brian Costello.

“ZeroFOX’s investment in enabling partners through sales, marketing, and technical expertise means that our partners can go-to-market faster, drive more demand, and secure more sustainable sources of revenue,” said Brian Costello, Vice President of Global Partnerships at ZeroFOX. “Both on-demand and white glove programs mean partners can confidently project the value that ZeroFOX brings to their portfolio.”

ZeroFOX expects to double partner contribution to the business this year, already acquiring the company’s largest customer in company history through a partner-based contract. Partners continue to broaden ZeroFOX’s capabilities into several verticals targeted widely by cyber criminals, including healthcare and financial services, and extend the company’s geographic footprint and expansion in EMEA, APAC and LATAM.

“ZeroFOX’s ability to bridge social, mobile, surface, and deep and dark web environments delivers a powerful digital risk protection solution in line with Exclusive Networks UK’s ethos of enabling our Partners to differentiate themselves through innovation and addressing the new challenges faced by end users,” said Mark Parr, Director of Strategic Vendors at Exclusive Networks UK. “Our partnership with ZeroFOX has helped drive growth and uncover new opportunities alongside our diverse range of partners. Furthermore, ZeroFOX's integrations with several of our existing technologies results in the creation of comprehensive and scalable solutions to be adopted by our broad partner base. The synergy between Exclusive Networks UK and ZeroFOX extends beyond technology with both organizations leading with a ‘can do’ approach and continually striving to innovate. This makes working together a natural choice.”

To find out more information about ZeroFOX, please visit our website at www.zerofox.com.

About ZeroFOX – ZeroFOX provides enterprises protection, intelligence and disruption to dismantle external threats to brands, people, assets and data across the public attack surface in one, comprehensive platform. With complete global coverage across the surface, deep and dark web and an Intel-backed artificial intelligence-based analysis engine, the ZeroFOX Platform identifies and remediates targeted phishing attacks, credential compromise, data exfiltration, brand hijacking, executive and location threats and more. The patented ZeroFOX Platform technology processes and protects millions of posts, messages and accounts daily across the social and digital landscape, spanning LinkedIn, Facebook, Slack, Instagram, Pastebin, YouTube, mobile app stores, domains, cloud-based email and more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ZeroFOX
Contact Press at ZeroFOX

PAN Communications
Kristen Hyle
401-219-9494
ZeroFOX@pancomm.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye